The EMA CHMP has recommended approval of MSD’s KEYTRUDA for two gynaecological cancers: endometrial and cervical.

A dark-money group has launched a multi-state bus tour to bring awareness to what they characterize as bad behavior by pharma ...

EU CHMP recommends approval of Merck’s Keytruda regimens as treatment for patients with two types of gynaecologic cancers ...

The revisions signal a shift toward looking at MS more as a biologically based disease, noted Xavier Montalban, MD, PhD, of ...

And the agency expanded the approval of bimekizumab (Bimzelx) to include psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis, UCB Announced.

The Mumbai-based startup’s products use AI to help identify and manage critical diseases at more than 3,000 imaging sites in ...

Few companies have attracted more attention this year than Nvidia. The chipmaker is on a roll thanks to the rapid rise of ...

AbbVie ABBV announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approving the ...

Injectable antibodies targeting PCSK9 have failed to take off as expected in the cholesterol-lowering market, but Merck & Co hopes to do much better with an oral alternative. MK-0616 has been ...

Merck KGaA’s ATR inhibitor cancer drug has been cleared for further clinical trials after it showed encouraging activity in a phase 1 study. Short for ataxia telangiectasia and Rad3-related ...

A new dose-finding study supported the potential of the carbonic anhydrase inhibitor as an alternative to CPAP machines.